BioAscent granted Controlled Drug Licence

Published: 13 January 2022

BioAscent has been granted a Controlled Drug Licence, allowing the company to store and test scheduled substances on behalf of its customers.

The licence permits BioAscent to possess, produce and supply controlled compounds and enables BioAscent's Biosciences team to carry out biological testing of these substances to aid customers' drug development programmes.

BioAscent has seen an increasing demand from customers focussed on novel drug development using controlled materials. This interest is driven by significant advances in our understanding of neuropsychiatric and neurodegenerative disorders, areas of expertise at BioAscent.

BioAscent's Chief Operating Officer, Sylviane Boucharens, said: "We are now able to handle controlled substances for our customers under this licence, including regulated substances. We are seeing significant interest in novel drug development programmes which involve the use of controlled substances, and customers need to find a partner that safely store, manage, test, and distribute such compounds. BioAscent's state-of-the-art facility is constructed to provide the maximum protection possible for valuable collections, giving customers assurance and peace of mind."

BioAscent's compound management customers benefit from rapid compound sourcing and aggregation, secure storage, up-to-date visibility of all samples and, rapid delivery of solids or liquids in any format, up to and including screen-ready assay ready plates.

Read more about BioAscent's state-ot-the-art facility, compound screening and compound management services.

Integrated Drug Discovery

Science-led drug discovery

Get in Touch

Let's talk about how we can maximise your drug discovery success.